Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
View Patent ↗Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described.
1. A method of enhancing blood coagulation in a subject, the method comprising:
orally administering to the subject a procoagulant amount of a non-anticoagulant sulfated polysaccharide (NASP) selected from the group consisting of N-acetyl-heparin (NAH), N-acetyl-de-O-sulfated-heparin (NA-de-o-SH), de-N-sulfated-heparin (De-NSH), de-N-sulfated-acetylated-heparin (De-NSAH), periodate-oxidized heparin (POH), chemically sulfated laminarin (CSL), chemically sulfated alginic acid (CSAA), chemically sulfated pectin (CSP), dextran sulfate (DXS), heparin-derived oligosaccharides (HDO), pentosan polysulfate (PPS), fucoidans, sulfated maltopentoses, sulfated beta-cyclodextrins, sulfated 6-Carboxyicodextrin in combination with a gastrointestinal epithelial barrier permeation enhancer in a manner sufficient to enhance blood coagulation in the subject,
wherein the gastrointestinal epithelial barrier permeation enhancer comprises a ratio of chitosan to bromelain sufficient to enhance permeation 2-fold or greater than would be achieved by the sum of chitosan or bromelain individually.
2. The method according to claim 1 , wherein the amount of NASP administered to the subject ranges from 0.01 mg/kg to about 100 mg/kg.
3. The method according to claim 1 , wherein the gastrointestinal epithelial barrier permeation enhancer comprises about 0.3% to about 3% chitosan and about 0.05 mg/mL to about 0.5 mg/mL bromelain.
4. The method according to claim 3 , wherein the gastrointestinal epithelial barrier permeation enhancer comprises about 3% chitosan and about 0.5 mg/mL bromelain.
5. The method according to claim 1 , wherein the method further comprising administering to the subject one or more factors selected from the group consisting of factor XI, factor XII, prekallikrein, high molecular weight kininogen (HMWK), factor V, factor VII, factor VIII, factor IX, factor X, factor XIII, factor II, von Willebrands factor, tissue factor, factor VIIa, factor Va, and factor Xa, factor IXa, factor XIa, factor XIIa, and VIIIa.
6. The method according to claim 1 , wherein the NASP is a fucoidan.
7. The method according to claim 6 , wherein the fucoidan is selected from the group consisting of Fucoidan 5307002, Fucus vesiculosus , max. MW peak 126.7 kD; Fucoidan VG49, Fucus vesiculosus , hydrolyzed sample of 5307002 of lower MW, max. MW peak 22.5 kD; Fucoidan VG57, Undaria pinnatifida , high charge (high sulphation, deacetylated); Fucoidan GFS (5508005), Undaria pinnatifida , depyrogenated; Fucoidan GFS (L/FVF-01091), Fucus vesiculosus , depyrogenated, max. MW peak 125 kD; Fucoidan GFS (L/FVF-01092), Fucus vesiculosus , depyrogenated, max. MW peak 260 kD; Fucoidan GFS (L/FVF-01093) and combinations thereof.
8. The method according to claim 1 , wherein the gastrointestinal epithelial barrier permeation enhancer comprises a ratio of chitosan to bromelain sufficient to enhance permeation 3-fold or greater than would be achieved by the sum of chitosan or bromelain individually.
9. The method according to claim 1 , wherein the gastrointestinal epithelial barrier permeation enhancer comprises a ratio of chitosan to bromelain of from 5:1 to 500:1.
10. The method according to claim 7 , wherein the gastrointestinal epithelial barrier permeation enhancer comprises a ratio of chitosan to bromelain of 5:1.
11. The method according to claim 1 , wherein chitosan is acylated chitosan.
12. The method according to claim 1 , wherein the subject has a bleeding disorder selected from the group consisting of a chronic or acute bleeding disorder, a congenital coagulation disorder caused by a blood factor deficiency, and an acquired coagulation disorder.
13. The method claim 12 , wherein the bleeding disorder is a blood factor deficiency of one or more factors selected from the group consisting of factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, and von Willebrand factor; a fibrinogen disorder; a prothrombin disorder; or a platelet dysfunction.
14. The method according to claim 1 , wherein the subject is in need of enhanced blood coagulation because of prior administration of an anticoagulant.
15. The method according to claim 14 , wherein the anticoagulant is selected from the group consisting of heparin, a coumarin derivative, tissue factor pathway inhibitor (TFPI), antithrombin III, lupus anticoagulant, nematode anticoagulant peptide (NAPc2), active-site blocked factor VIIa (factor VIIai), factor IXa inhibitors, factor Xa inhibitor, factor Va inhibitor, factor VIIIa inhibitor, thrombin inhibitor, and an antibody that binds a clotting factor selected from the group consisting of Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XIII, Factor II, Factor XI, Factor XII, von Willebrands factor, prekallikrein, and high molecular weight kininogen (HMWK).
16. The method according to claim 1 , wherein the method is a method of inhibiting TFPI activity in the subject.